Blog

Aug 26, 2024, 20:37

Incredibly relevant study on immunotherapy in msi-h mCRC – Foxpaws Fauxpas

Foxpaws Fauxpas shared a post on X:

“Fantastic and incredibly relevant study on immunorx in msi-h mCRC from ACTREC-TMC, Tata Memorial Hospital, Mehak Trikha, Laboni Sarkar, Anant Ramaswamy, and Prof Vikas Ostwal

Nivo at 20 mg and 40 mg. Crazy trailblazing.

Dr Amol Akhade– thoughts.“

Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study)

Authors: Mehak Trikha, Laboni Sarkar, Aditya Dhanawat, Noorzia Syed, Himanshu Gujarathi, Manan Vora, A Sree Sivakumar Raja, Prabhat Bhargava, Anant Ramaswamy, Sarika Mandavkar, Avanish Saklani, Rajiv Kumar Kaushal, Munita Bal, Omshree Shetty, Subhash Yadav, and Vikas Ostwal.

Incredibly relevant study on immunotherapy in msi-h mCRC - Foxpaws Fauxpas

Source: Foxpaws Fauxpas/X

ACTREC-TMC Aditya Dhanawat Amol Akhade Anant Ramaswamy cancer Foxpaws Fauxpas Laboni Sarkar Mehak Trikha Omshree Shetty OncoDaily Oncology Prof Vikas Ostwal Subhash Yadav Tata Memorial Hospital Vikas Ostwal

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage